Posted on June 8, 2015 by Sitemaster
For some 15+ years there have been subsets of patients and physicians who have believed strongly that adding a 5α-reductase inhibitor (5-ARI) like finasteride or dutasteride to an anti-androgen would quite certainly aid in the prevention of prostate cancer progression because such a regimen would reduce levels of dihydrotestosterone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 5-ARI, ADT2, ADT3, anti-androgen, castration-resistant, CRPC, non-metastatic, outcome, trial | 30 Comments »
Posted on May 18, 2015 by Sitemaster
Earlier this year results from the TERRAIN trial reported that adding enzalutamide (Xtandi) to LHRH agonist therapy was more effective than adding the antiandrogen bicalutamide in men with metastatic, castration-resistant prostate cancer ( M1 CRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: anti-androgen, bicalutamide, castration-resistant, enzalutamide, STRIVE | 1 Comment »
Posted on March 25, 2009 by Sitemaster
We have separately addressed data from a 15-year follow-up of a population-based Swedish screening study. Other reports today deal with:
- The impact of dietary and supplemental zinc on prostate cancer risk
- Prediction of risk for loss/preservation of erectile function post- prostatectomy
- Anti-androgen therapy and brachytherapy: options and outcomes … READ MORE ….
Filed under: Management, Prevention, Risk, Treatment | Tagged: anti-androgen, brachytherapy, diet, erectile function, maximal androgen deprivation, monotherapy, potency, prediction, risk, supplement, surgery, zinc | Leave a comment »
